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Background. A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-regulates HIV RNA expres-
sion within resting CD4+ T cells of treated, aviremic human immunodeficiency virus (HIV)–positive partici-
pants. The ability of multiple exposures to VOR to repeatedly disrupt latency has not been directly measured, to
our knowledge.
Methods. Five participants in whom resting CD4+ T-cell–associated HIV RNA (rc-RNA) increased after a single
dose of VOR agreed to receive daily VOR Monday through Wednesday for 8 weekly cycles. VOR serum levels,
peripheral blood mononuclear cell histone acetylation, plasma HIV RNA single-copy assays, rc-RNA, total cellular
HIV DNA, and quantitative viral outgrowth assays from resting CD4+ T cells were assayed.
Results. VOR was well tolerated, with exposures within expected parameters. However, rc-RNA measured after
dose 11 (second dose of cycle 4) or dose 22 (second dose of cycle 8) increased significantly in only 3 of the 5 partic-
ipants, and the magnitude of the rc-RNA increase was much reduced compared with that after a single dose. Changes in
histone acetylation were blunted. Results of quantitative viral outgrowth and other assays were unchanged.
Conclusions. Although HIV latency is disrupted by an initial VOR dose, the effect of subsequent doses in this pro-
tocol was much reduced. We hypothesize that the global effect of VOR results in a refractory period of ≥24 hours. The
optimal schedule for VOR administration is still to be defined.
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Effective antiretroviral therapy allows human immuno-
deficiency virus (HIV)–infected individuals to live long
and productive lives [1].However, HIV infection remains
incurable in part owing to the presence of quiescent,
replication-competent provirus within a long-lived
population of memory T cells, capable of reigniting
new rounds of infection if therapy is interrupted. This
latent pool of virus is established within days of infec-
tion and is refractory to the actions of the immune sys-
tem or of current therapy [2–4]; thus, HIV infection will
require lifetime treatment unless persistent, latent infec-
tion is purged.
After integration of HIV DNA into the cellular
genome, the HIV long terminal repeat promoter exists
in a nucleosome-bound conformation and is trans-
criptionally silent without stimulation of the infected
cell. Studies by several laboratories have suggested that
multiple mechanisms maintain the quiescent state of
the HIV promoter [5–7]. Among the well-characterized
factors that maintain latency are cellular histone
deacetylases (HDACs) that deacetylate many cellular
proteins, including histones. There are 4 classes of
HDACs: class I includes HDACs 1, 2, 3 and 8; class
IIa, HDACs 4, 5, 7 and 9; class IIb, HDACs 6 and 10;
and class IV, HDAC 11 (class I is nuclear, and the
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others are cytoplasmic). The class III HDACs, sirtuins, are not
regulators of HIV transcription and are not responsive to tradi-
tional inhibitors of HDAC activity [7, 8].
Multiple studies have shown that HDAC are recruited to the
HIV promoter by transcription factor complexes and maintain
the long terminal repeat in a transcriptionally silent state.
HDACs 1, 2, and 3 mediate the repression of HIV transcription
[9, 10]. When studied in cell line and primary cell models of
HIV latency, HDAC inhibitors lead to acetylation of lysine res-
idues on histone tails, an event associated with induction of
transcription at the HIV promoter [11–13].
In a recent clinical trial, the administration of a single dose of
the HDAC inhibitor vorinostat (VOR) to 8 participants receiv-
ing suppressive antiretroviral therapy resulted in an increase of
HIV RNA within resting CD4+ T cells, demonstrating for the
first time disruption of HIV latency in vivo [14]. In this study
design the pharmacokinetic profile of VOR was measured after
an initial 400-mg dose, several weeks before a second, isolated
dose of VOR. After this later dose, HIV RNA induction was
specifically demonstrated within pools of resting, not total,
CD4+ T cells (hence the term rc-RNA). However, the ability
of multiple doses of VOR to continuously disrupt HIV latency
has not yet been clearly demonstrated.
In this study, we sought to determine whether administration
of multiple doses of VOR would result in repeated induction of
rc-RNA, in association with repeated increases in cellular acet-
ylation, and whether such repetitive induction of bursts of viral
gene expression for the latent proviral would be associated with
a concurrent depletion of resting CD4+ T-cell infection.
MATERIALS AND METHODS
Study Participants
All HIV-infected participants were receiving stable standard-
of-care antiretroviral therapy with plasma HIV-1 RNA < 50
copies/mL and a CD4+ cell count of >300/µL for ≥6 months be-
fore enrollment.Written informed consent was obtained fromall
participants before study enrollment. Approval was obtained
from the University of North Carolina (UNC) institutional bio-
medical review board and the Food and Drug Administration,
and the study was registered at ClinicalTrials.gov (NCT01319383).
Five of the 8 participants described elsewhere [14] reenrolled in
this follow-on study, in which they received 22 cyclical doses of
VOR during a 12–16-week period.
The VOR dosing schema was empirically derived from on-
cology studies, with the goal of achieving maximal drug expo-
sure with negligible I toxic effects. VOR is most often dosed at
400 mg/d, the dose that induced HIV expression in our original
study [14]. Therefore, we elected to give daily VOR Monday
through Wednesday for 4 weekly cycles, followed by a rest
and evaluation period and then 4 more cycles.
Because of the limited number of leukapheresis evaluations
that could be performed to precisely measure HIV RNA and
replication-competent HIV within the circulating resting
CD4+ T-cell population, rc-RNA was assessed at the last dose
of the fourth and eighth cycle of VOR administration, and
the frequency of resting cell infection was reassessed at the
end of the eighth cycle. Peripheral blood cells for research assays
were obtained by leukapheresis performed at baseline before
initiation of multiple-dose VOR administration and again 6
hours after doses 11 and 22 of VOR.
Analysis of Total Histone Acetylation
Peripheral blood mononuclear cells (PBMCs) were collected
and viably frozen before and after VOR dosing. Cells were
quickly thawed for batched assays by gentle addition of cold
washing/staining solution (1× phosphate-buffered saline, 2%
fetal bovine serum, and 0.09% sodium azide). Cells then washed
and fixed with prewarmed BD Phosflow Fix Buffer (BD Biosci-
ences; catalog No. 557 870) at 37°C for 10 minutes and then
washed and permeabilized with ice cold BD Phosflow Perm
Buffer II (BD Biosciences; catalog No. 558052) for 30 minutes.
Cells were then washed and stained with anti-acetyl-histone 3
phycoerythrin-labeled antibody (Millipore; catalog No.
FCABS325PE) or phycoerythrin-labeled rabbit immunoglobu-
lin G antibody (Santa Cruz Biotechnology; catalog No. sc-3745)
for 60 minutes, washed twice, and resuspended in 2% parafor-
maldehyde solution for analysis by flow cytometry (Cyan ADP
Analyzer; Beckman Coulter) at the UNC Flow Cytometry Core
Facility. Small lymphocytes, identified by forward and side scat-
ter, were analyzed (Supplementary Figure 1).
Pharmacokinetic Analysis
Serum was collected for pharmacokinetic assays and stored at
−70°C until analysis. The VOR concentrations were measured
in human serum using a modification of the method of Musson
et al [15]. Individual serum concentrations were used to estimate
the following VOR pharmacokinetic variables: area under the
curve for 0–24 hours, maximum concentration, and apparent
terminal half-time. WinNonlin Phoenix (Certara) was used for
the calculations. The apparent terminal half-time was estimated
from the best fit of a single exponential to the log-linear portion
of the serum concentration/time curve, using unweighted linear
regression. The area under the receiver operating characteristic
curve for 0–24 hours was calculated using the linear up/log
down method. The maximum concentration and Tmax were ob-
tained by inspection of the concentration-time data [14].
Quantitative Viral Outgrowth Assay
Lymphocytes were obtained by continuous-flow leukapheresis
and isolation of resting CD4+ T cells. Recovery and quantification
of replication-competent virus was performed as described else-
where [16].Briefly, approximately 50 million resting CD4+ T cells
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were plated in replicate limiting dilutions of 2.5 million (18 cul-
tures), 0.5 million (6 cultures), or 0.1 million (6 cultures) cells per
well, activated with phytohemagglutinin (Remel), a 5-fold excess
of allogeneic irradiated PBMCs from a seronegative donor, and
60 U/mL interleukin 2 for 24 hours. Cultures were washed and
cocultivated with CD8-depleted PBMCs collected from selected
HIV-seronegative donors screened for adequate CCR5 expres-
sion. Culture supernatants were harvested and assayed for virus
production by p24 antigen-capture enzyme-linked immunosor-
bent assay (ABL). Cultures were scored positive if p24 was detect-
ed at day 15 and was increased in concentration at day 19. The
number of resting CD4+ T cells in infected units per billion was
estimated using a maximum likelihood method [17].
Measurement of HIV RNA
In vivo response to VOR dosing was measured as described
elsewhere, with minor modifications [14]. Immediately after
leukapheresis, resting CD4+ T cells were isolated and plated at
1 million cells/well, pelleted, snap frozen, and stored at −80°C.
Total RNA was isolated from 36 replicates of 1 million resting
cells using the Magmax 96 Total RNA isolation kit (Life Tech-
nologies) and following the manufacturer’s protocol. Comple-
mentary DNA (cDNA) was synthesized in duplicate from
DNase-treated, isolated RNA using the SuperScript III First-
Strand Synthesis SuperMix kit (Invitrogen), according to the
manufacturer’s procedures. Reverse transcriptase was omitted
from duplicate wells of each treatment condition, which served
as controls for DNA contamination. Duplicate polymerase
chain reaction (PCR) amplification of duplicate cDNAwas per-
formed using the Biorad FX96 Real-Time PCR machine and
primers and probe published elsewhere [18]. A standard curve
was generated for each PCR reaction, as described elsewhere
[12]. Results of the 4 PCR replicates representing each of the
original 36 pools of RNAwere averaged, and the standard devi-
ation was determined for each condition. The Wilcoxon rank
sum test was used to calculate the statistical significance of
changes within each participant.
Single-copy assays of plasma HIV-1 RNA were performed as
described elsewhere [19]. For droplet digital PCR assays, RNA
and DNA were isolated from participant PBMCs collected at
baseline and at doses 11 and 22, using the AllPrep DNA/RNA
Mini Kit (Qiagen). DNA was assayed for HIV content using
primer/probe sets in HIV pol and for cellular DNA content
using a target in the 30-kDa subunit of RNAse P, as described
elsewhere [20]. Extracted RNA was reverse transcribed using a
Bio-Rad iScript cDNA kit and assayed in parallel for targets in
HIV Gag (primers SK431/SK462 and probe SK102 [21] and in
the 3′ long terminal repeat of polyadenylated HIV-1 transcripts
[22]. Copy numbers of HIV RNA were normalized to the total
RNA input to the cDNA reaction, measured by absorption at
260 nmwith a Nanodrop 2000 spectrometer (Thermo Scientific).
RESULTS
Clinical Outcome of Multiple Doses of VOR
Previously, HIV latency was disrupted in vivo by administration
of a single 400-mg dose of VOR [14]. Five of the 8 participants
reported in that study subsequently reenrolled in this follow-on
study, in which they received 22 cyclical doses of VOR during a
12–16-week period. Because of the limited number of leukaphe-
resis evaluations that could be performed to precisely measure
HIV RNA and replication-competent HIV within the circulat-
ing resting CD4+ T-cell population, rc-RNA was assessed at the
last dose of the fourth and eighth cycle of VOR administration,
and the frequency of resting cell infection was reassessed at the
end of the eighth cycle. All participants were male and white,
with a mean age of 54 years. Participants were all virally sup-
pressed (<50 copies/mL) for ≥2 years with a mean CD4+ cell
count of 709 at study enrollment (Table 1).
More than 6 months after the single doses for pharmacoki-
netics and rc-RNA [14], a new baseline rc-RNA was measured
and then participants self-administered 400 mg of VOR every
24 hours for 3 days, followed by 4 days with no VOR. This
weekly cycle was repeated 4 times except on the 4th week
Table 1. Clinical Characteristics of Study Participantsa
Characteristic Patient 1 Patient 2 Patient 3 Patient 7 Patient 8
Treated during AHI Yes No
Age, y 63 57 42 52 54
Duration of ART, y 6 10 3 13 27
Duration of viral suppression, yb 3 7 2 3 4
Lowest CD4+ T-cell count recorded (cells/μL) 277 170 232 81 195
Peak plasma HIV-1 RNA recorded, copies/mL 84 545 454 (during AHI) 734 63 620 382 966 71 928
CD4+ T-cell count at study entry (cells/μL) 705 473 476 747 1147
Abbreviations: AHI, acute HIV infection; ART, antiretroviral therapy; HIV, human immunodeficiency virus.
a All patients were white and male.
b Viral suppression is defined as <50 HIV RNA copies/mL.
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only 2 doses were given, for a total of 11 doses. Leukapheresis
was performed 6 hours after the 11th dose. This was followed by
a 4–8-week interval, and then identical subsequent cycles of
VOR Monday through Wednesday with 4-day rest periods for
an additional 11 doses (Figure 1). Leukapheresis was performed
for the second time 6 hours after the 22nd dose. Antiretroviral
therapy was never interrupted.
The dosing regimen was well tolerated by all participants except
for some mild, transient gastrointestinal symptoms and headache,
which did not approach grade I severity levels. All participants ex-
hibited a 15%–35% decline in platelet counts by the fourth cycle
of dosing, which recovered during the 4–8-week rest interval, and
recurred during the 7th or 8th cycle of dosing. However, this tran-
sient thrombocytopenia reached grade I toxicity level during only
a single visit for a single study participant. No other clinical events
or drug-related toxic effects were observed.
Owing to the theoretical concern that systemic disruption of
latent HIV infection might induce CNS toxic effects, resulting
from an inflammatory or neurotoxic response in the brain, a
neurocognitive battery of tests was administered just before
multiple VOR dosing and at the end of the study. No significant
changes were measured.
Multiple-Dose VOR Pharmacokinetics
To verify that drug exposure after multiple doses of VOR was
uniform, as has been reported in oncology studies [23], pharma-
cokinetic analysis was performed on serum samples collected
4 and 24 hours after administration of dose 11 and 22 of VOR,
and values compared to steady state levels obtained after admin-
istration of a single dose. As shown in Figure 2, exposure to VOR
Figure 1. Protocol schema for multiple-dose vorinostat testing. Abbreviations: CA-RNA, cell-associated HIV RNA; IUPM, infected units per million; M,
Monday; T, Tuesday; VOR, vorinostat; W, Wednesday.
Figure 2. Exposures to vorinostat (VOR) at weeks 4 and 8 are similar to
single-dose exposure. Abbreviations: AUC, area under the receiver operat-
ing characteristic curve; Cmax, maximum concentration; IQR, interquartile
range; PK, pharmacokinetics.
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after multiple doses was similar to that observed after a single
dose. Most of the observed concentrations after multiple dosing
fell within the inter-quartile range of the first dose; not markedly
dissimilar from values seen after single isolated doses (Figure 2).
Effect of Multiple Doses of VOR on rc-RNA and Histone
Acetylation
To assess the efficacy of multiple doses of VOR on the CD4+
T-cell reservoir, we measured the quantity of HIV-1 gag RNA
in 36 pools of 1 million freshly isolated resting CD4+ T cells at
a baseline time point and after doses 11 and 22 of VOR, in par-
allel with flow-based measures of total cellular histone acetylation
(Figure 3A and 3B). In contrast to the uniform increase of rc-
RNA in each participant after a single isolated dose for VOR in
the previous [14], rc-RNA was increased in this study only after
both doses 11 and 22 for participant 8 and after 1 of the 2 doses
evaluated in participants 3 and 7. Although rc-RNA did increase
at ≥1 time point in 3 of 5 participants and at 4 of the 10 time
points evaluated, in only 1 case was the magnitude of rc-RNA in-
duction comparable to that seen in the previous study [14],when
the dose evaluated was not closely preceded by an earlier VOR
exposure. A signed rank test of the log-fold change of HIV
RNA from baseline to dose 11 and from baseline to dose 22
for these 5 study participants showed a trend toward an increase
at dose 11, which did not achieve statistical significance (P = .06),
but no such trend at dose 22 (P = .625). However, the increase
was >1.5-fold at only a single time point in a single participant
(Figure 3B), whereas rc-RNA uniformly increased 1.5–5-fold in
all participants after the initial doses of VOR [14]. In agreement
with this observation, the fold induction of total cellular H3 acet-
ylation was also reduced after doses 11 and 22, compared to that
seen in the previous study [14].
As another measure of persistent HIV infection, we also mea-
sured total PBMC-associated HIV DNA and PBMC-associated
HIV RNA by a droplet digital PCR method. Because these stud-
ies were performed in total PBMCs and not in sorted resting
CD4+ cells, and because of the different amplification tech-
niques used, we could not directly compare these measures
and resting CD4+ T-cell rc-RNA values (given above). In
PBMCs, however, no significant change was observed in HIV
DNA or RNA from baseline to either dose 11 or 22 (Table 2).
Single-copy plasma HIV-1 RNA assays did not show increas-
es in plasma viremia in temporal association with VOR dosing
in most patients, but levels of viremia were low, and any changes
could not be distinguished from biological or PCR variation in
this small cohort (Supplementary Table 3). We also we
Figure 3. A, Relative human immunodeficiency virus (HIV) 1 gag RNA copies per million resting CD4+ T cells at study baseline and after doses 11 and 22.
*P < .05 (significant increase from baseline; Mann–Whitney test). B, Fold change from baseline of relative HIV-1 gag RNA copies per million resting CD4+
T cells (blue) and total H3 acetylation in small lymphocytes (red ) at baseline and after doses 11 and 22 (single-dose data from Archin et al [14]).
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evaluated the frequency of replication-competent latent HIV in-
fection by performing quantitative viral outgrowth assay on
resting CD4+ T cells obtained at baseline and after doses 11
and 22 (Figure 4). No significant change in this measurement
was observed.
DISCUSSION
Archin et al [14] first reported the disruption of HIV latency as
measured by increased levels of resting CD4+ T-cell–associated
HIV RNA (rc-RNA) immediately after a single dose of VOR.
Preliminary reports have been published of the effect of 14
daily doses of VOR [24] and thrice-weekly, every-other-week
dosing of panobinostat [25], although the cell populations stud-
ied and assay methods differ. Given the strong evidence that
VOR can disrupt HIV latency, our current study focused on
measurements of the response to VOR after multiple prior
VOR doses. Because of the resources necessary for this study,
only 3 leukapheresis-based evaluations could be performed in
each participant. In addition to assessing HIV RNA expression
in resting CD4+ cells, we also sought evidence of depletion of
persistent HIV infection after durable VOR exposure, mindful
of the evidence in a laboratory model system suggesting that the
disruption of HIV latency might not lead to immediate clear-
ance of the substantial majority of latently infected cells [26],
as measured by currently available assays.
When used in oncology, VOR is generally dosed daily; twice-
daily dosing is used in some settings [27]. Because total cellular
histone acetylation had returned nearly to baseline levels in our
initial study [14], we tested daily dosing with VOR, with rest in-
tervals each week to minimize toxic effects. Participants re-
ceived 8 weekly cycles of VOR, with a 4–8-week interval
between cycle 4 and 5, to reduce the inconvenience of frequent
required evaluations and to distribute the blood loss incurred by
required phlebotomy. VOR given in this setting was very well
tolerated, with only mild and reversible declines in platelet
counts seen by cycles 4 and 8. No significant gastrointestinal
toxic effects were seen. Although the evaluation is preliminary,
we saw no effect of VOR on neuropsychiatric measures [28].
In contrast to the changes seen after an initial dose of VOR,
in 5 participants who received a total of 22 400-mg doses of
VOR during a 4-month period, cellular acetylation and rc-
RNA were increased only minimally when measured shortly
after doses 11 and 22. Given the complex modulation of numer-
ous cellular genes by VOR and the fact that cellular acetylation
remains modestly up-regulated 24 hours after VOR exposure,
compensatory cellular effects that follow VOR administration
may blunt subsequent response to additional VOR doses during
the 24-hour dosing interval tested. We hypothesize that a longer
interdose interval may be required to allow cellular mechanisms
to be resensitized to HDAC inhibition and to observe robust
and reproducible induction of latent HIV proviral expression.
This result was unexpected, but there has been surprisingly little
examination of the kinetic effects of HDAC inhibitors on cellu-
lar gene expression and protein modification or after multiple
HDAC inhibitor exposures [29, 30].
Table 2. Droplet Digital Polymerase Chain Reaction Assays of
HIV RNA and DNA
Patient and
Assay Timing










Baseline 23.6 31.6 135.3
Dose 11 17.1 22.5 140
Dose 22 13.4 14.6 116.8
Patient 2
Baseline 14.5 9.4 12.2
Dose 11 23.6 28.4 7.5
Dose 22 23.1 30.6 21.2
Patient 3
Baseline 4.1 24.8 290.8
Dose 11 8.6 33.5 182.9
Dose 22 6.3 24.6 285.5
Patient 7
Baseline 73.9 108.8 575.2
Dose 11 98.4 219.2 314.5
Dose 22 79.7 136.8 788.9
Patient 8
Baseline 0 16.7 36.6
Dose 11 0 20.3 45.7
Dose 22 0 19.6 57.8
Abbreviation: HIV, human immunodeficiency virus.
Figure 4. The frequency of replication-competent human immunodefi-
ciency virus infection within resting CD4+ T cells was measured at baseline
and after doses 11 and 22. Abbreviations: IUPM, infectious units per billion;
VOR, vorinostat.
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A complex, multiphasic cascade of host gene expression is trig-
gered after exposure to inhibitors. In primary CD4+ T cells stud-
ied ex vivo after a single exposure to VOR, modest up-regulation
was observed for 1000 genes, as well as down-regulation of 847
genes [29]. The downstream effects of these changes and how
they affect the cellular and proviral response to a second exposure
to VOR have not been studied. For example, one recent hypoth-
esis holds that VOR induces HIV expression via the release of
pTEF-b [31]. If this is so, pTEF-b mobilized by an initial expo-
sure to VOR might not reaccumulate in time to allow a response
to a second exposure within 24 hours.
HDAC inhibitors are currently leading candidates for use as
therapeutic agents to attack latent HIV infection. There is a
widely held expectation that eradication of HIV infection will
require the use of combination therapy to efficiently disrupt la-
tent infection and the use of vaccines or immunotherapy to as-
sist in clearing latent HIV infection [32–34]. Our current
findings illustrate that careful study of the effects of each inter-
vention, and the interactions of these interventions, will be re-
quired to advance toward the ultimate goal of therapies that can
cure HIV infection.
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